血管疾患の危険因子としてのプラズマ全体システイン:欧州協調行動プロジェクト
L El-Khairy1, P M Ueland, H Refsum
1LOCUS for Homocysteine and Related Vitamins, University of Bergen, Bergen, Norway. lina.el-khairy@smis.uib.no
Circulation
|May 31, 2001
まとめ
血の総システイン (tCys) は,血管疾患のリスクとのU型リンクを示し,低レベルと高レベルの両方がリスクを増加させます. これは,心血管疾患のリスク因子として知られるホモシステイン総量 (tHcy) と対照的です.
科学分野:
- バイオケミストリー バイオケミストリー
- 心血管医学 心血管医学
- エピデミオロジー エピデミオロジー
背景:
- 血総ホモシステイン (tHcy) の上昇は,心血管疾患 (CVD) のリスク要因として認識されています.
- プラズマ全体システイン (tCys) とCVDリスクとの関連は,tHcy.との代謝関連にもかかわらず,まだ十分に調査されていない.
研究 の 目的:
- プラズマ全体のシステイン (tCys) レベルと冠動脈,脳,外周血管の血管疾患のリスクとの関係を調査する.
主な方法:
- 血管疾患の患者750人と欧州9カ国の800人の対照群を対象としたケース・コントロール研究.
- 計測されたtCys,tHcy,葉酸,B6 ,B12 ,およびクレアチニンの血濃度.
- 従来の心血管疾患の危険因子に調整したものです.
主要な成果:
- tCysレベルと血管疾患の全体的なリスクとの間に有意なU形の関係が観察されました.
- 低TCysレベル (<=225ミクロモール/L) は,調整されたリスクが2.1 (95%CI 1.2〜3.6) であることを示した.
- 高いtCysレベル (>300マイクロモル/L) は,基準レベル (250-275マイクロモル/L) と比較して1.6 (95%CI1.1〜2.3) の調整されたリスクを示した.
- 血管床によって異なる投与量反応関係: 外周および脳血管疾患のU型,冠動脈疾患の弱い陽性.
結論:
- 血の総システイン (tCys) は,心血管疾患のリスクとU型で有意な関連性を示しています.
- この関係は,tHcy,クレアチニン,および他のCVDリスク要因を調整した後も維持されます.
- この発見は,tCysが血管疾患リスクの潜在的,独立したマーカーであることを強調しています.
さらに関連する動画
関連する概念動画
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
765
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
973
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
973
Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


